A Clinical Decision Support System to Stratify the Temporal Risk of Diabetic Retinopathy
Michele Bernardini, Luca Romeo, Adriano Mancini and 1 more
IEEE Access · 2021
doi:10.1109/access.2021.3127274 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Diabetic Retinopathy (DR) is the most common and insidious microvascular complication of diabetes, and can progress asymptomatically until a sudden loss of vision occurs. Although DR is prevalent nowadays, its prevention remains challenging. The multiple aim of this study was to predict the risk of developing DR as diabetic complication (task 1) and, subsequently, temporally stratify the DR risk (task 2) using electronic health records data. To perform these objectives, a novel preprocessing procedure was designed to select both control and pathological patients, and moreover, a novel fully annotated/standardized 120K dataset from multiple diabetologic centers was provided. Globally, although the Extreme Gradient Boosting model offers satisfying predictive performance, the Random Forest model obtained the best predictive performance to solve task 1 and task 2, reaching the best Area Under the Precision-Recall Curve of 72.43 % and 84.38 %, respectively. Also the features importance extracted from the best Machine Learning (ML) models is provided. The proposed Artificial Intelligence-based solution was proven to be capable of generalizing across different diabetologic centers while ensuring high-interpretability. Moreover, the proposed ML solution is currently being adopted as a Clinical Decision Support System in several diabetologic centers for DR screening and follow-up purposes.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.